Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OSBP | P22059 | 4/20 | 0.64 |
| ▸ | RORC | P51449 | 3/20 | 0.64 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.63 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.57 |
| ▸ | USP2 | O75604 | 2/20 | 0.57 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.52 |
| ▸ | OSBP2 | Q969R2 | 2/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | DHCR24 | Q15392 | 1/20 | 0.48 |
| ▸ | POLA1 | P09884 | 1/20 | 0.48 |
| ▸ | GPR183 | P32249 | 2/20 | 0.48 |
| ▸ | CRYAB | P02511 | 1/20 | 0.48 |
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGAV | P06756 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6392994 | 1.00 | OSBP (0.64) | OSBPRORCNR1H3PTPN1SRD5A1 | |
| SCHEMBL6393358 | 0.92 | PTPN1 (0.74) | OSBPRORCNR1H3PTPN1SRD5A1 | |
| SCHEMBL27563313 | 0.92 | PTPN1 (0.74) | OSBPRORCNR1H3PTPN1SRD5A1 | |
| SCHEMBL6392384 | 0.92 | PTPN1 (0.74) | OSBPRORCNR1H3PTPN1SRD5A1 | |
| SCHEMBL6389412 | 0.92 | PTPN1 (0.74) | OSBPRORCNR1H3PTPN1SRD5A1 | |
| SCHEMBL6388546 | 0.92 | PTPN1 (0.74) | OSBPRORCNR1H3PTPN1SRD5A1 | |
| SCHEMBL6389389 | 0.88 | NPC1L1 (0.64) | OSBPRORCNR1H3PTPN1SRD5A1 | |
| SCHEMBL6387054 | 0.86 | PTPN1 (0.56) | OSBPRORCNR1H3PTPN1SRD5A1 | |
| SCHEMBL6389203 | 0.85 | PTPN1 (0.65) | OSBPRORCNR1H3PTPN1SRD5A1 | |
| SCHEMBL6390390 | 0.85 | PTPN1 (0.65) | OSBPRORCNR1H3PTPN1SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004382-A1 | Meiosis regulating compounds | GRONDAHL CHRISTIAN (DK) | 2005-01-06 | — | — | US | disclosed |
| US-6759400-B2 | Meiosis regulating compounds | NOVO NORDISK A/S (DK) | 2004-07-06 | — | — | US | disclosed |
| EP-0946584-B1 | Meiosis regulating compounds | NOVO NORDISK AS (DK) | 2003-04-23 | — | — | EP | disclosed |
| US-20030032824-A1 | Meiosis regulating compounds | GRONDAHL CHRISTIAN (DK) | 2003-02-13 | — | — | US | disclosed |
| US-6486145-B2 | STEROL DERIVATIVE USEFUL IN TREATMENT OF FERTILITY | NOVO NORDISK A/S (DK) | 2002-11-26 | — | — | US | disclosed |
| US-20010005757-A1 | Meiosis regulating compounds | GRONDAHL CHRISTIAN (DK) | 2001-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032824-A1 | Meiosis regulating compounds | MNS1, NR5A1, NASP | OSBP 95/4885RORC 1053/4885NR1H3 340/4885 |
| US-20010005757-A1 | Meiosis regulating compounds | MNS1, NR5A1, NASP | OSBP 95/4885RORC 1053/4885NR1H3 340/4885 |
| US-20050004382-A1 | Meiosis regulating compounds | NASP, MNS1, NR5A1 | OSBP 95/4885RORC 687/4885NR1H3 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.